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Purpose:  Rhinitis and asthma usually occur together. There are increasing evidences that allergic rhinitis (AR) may influence the clinical course of 
asthma. The aim of this study is to evaluate clinical parameters and therapeutic response in patients with between asthma and asthma with AR. 
Methods:  Four-hundred eighty-five patients with asthma and 428 asthmatics with AR, who had lesser than 50 years old and smoked less than 10 
pack-years were recruited. We compared FEV1 and FEV1/FVC following bronchodilator, atopy, IgE, emphysema on HRCT, and aspirin intolerance be-
tween two groups. Also we compared physiologic fixed airway obstruction defined using FEV1/FVC and FEV1 less than 75% following anti-asthmat-
ic drug for 1 year.  Results:  46.8% (428/913) asthmatics suffered from AR. There were no differences of total IgE, body mass index, PC20, sputum 
eosinophils and emphysema on HRCT between two groups. The age in asthmatics was higher than that in those with AR. FEV1/FVC was lower in 
asthmatics than in those with AR. The prevalence of atopy was higher in asthmatics with AR than in asthmatics. Aspirin intolerance was higher in 
asthmatics with AR than in asthmatics (42/218 versus 13/109, P=0.001). Fixed airway obstruction were more observed in asthmatics than in those 
with AR (39/319 versus 28/355, P=0.001) after anti-asthmatic drug for 1 year.  Conclusions:  Asthmatics with AR had more atopy and aspirin intol-
erance than asthmatics, and asthmatics had poor response to anti-inflammatory drugs than those with concurrent rhinitis, indicating that asthmatics 
have more fixed airway obstruction than those with concurrent rhinitis.
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INTRODUCTION
Close association exists between allergic rhinitis (AR) and 
asthma. There are increasing evidences that AR may influence 
the clinical course of asthma adults.
1-6
Putative mechanisms linking rhinitis to asthma are explained 
by direct and indirect effect.
7 The direct effects are naso-bron-
chial reflex, postnasal drip of inflammatory cells and/or media-
tors from the nose into the lower airways, and absorption of in-
flammatory cells and/or mediators from the nose into the sys-
temic circulation and ultimately the lung. The indirect effects 
are nasal obstruction causing reduction in filtration, humidifi-
cation, and warming function of the nose.
8
Rhinitis patients showed a lower degree of bronchial hyperre-
sponsiveness (BHR) to allergen than asthmatics, but respond-
ed to allergen inhalation with changes in airway inflammation 
and in maximal response plateau very similar to asthmatics.
8 
The differences between asthma and AR in symptoms depend 
on a quantitatively different response to environmental aller-
gen inhalation.
8
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Eosinophilic inflammation may be present in subjects with 
AR and BHR even when there are no symptoms of asthma.
9
There is a little report about comparative data of clinical and 
therapeutic response between asthmatics and asthmatics with 
AR. The aim of this study is to evaluate clinical parameters and 
therapeutic response to asthma between asthmatics and asth-
matics with AR.
MATERIALS AND METHODS
Patients
Subjects were recruited from the Genome Research Center for 
Allergy and Respiratory Diseases at Soonchunhyang University, 
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Bucheon, Korea, and Chunan Hospital, Chunan, Korea. All pa-
tients were diagnosed by a physician and met the definition of 
asthma set forth in the Global Initiative for Asthma (GINA) 
guidelines.
10 All patients had a history of dyspnea and wheezing 
during the previous 12 months, plus one of the following: 1) 
>15% increase in FEV1 or >12% increase plus 200 mL following 
inhalation of a short-acting bronchodilator; 2) <10 mg/mL PC20 
methacholine; and 3) >20% increase in FEV1 following 2 weeks 
of treatment with inhaled steroids and long-acting bronchodi-
lators.
10
Symptoms of allergic rhinitis were assessed by questionnaires 
on Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 up-
date.
11 The symptoms of AR is on responses to questionnaires 
on ‘do you have any nasal allergies including anterior or poste-
rior rhinorrhoea, sneezing, nasal blockage and/or itching of the 
nose?’ and ‘do you have your symptoms occur during two or 
more consecutive days for more than 1 hour on most days?’ 
and ‘do you have symptoms during season or perennial?’ and 
‘do your symptoms impair of daily activities and school or 
work?’ . All patients were diagnosed by a physician and met the 
definition of AR set forth in the Allergic Rhinitis and its Impact 
on Asthma (ARIA) 2008 update.
11
The exclusion criteria included greater than 10 pack-years 
smoking, less than 20 or more than 50 years old, parenchymal 
lung disease apparent on chest radiography, diffusing capacity 
less than 80%, severe uncontrolled diabetes mellitus, and renal, 
hepatic, or cardiac failure. This study was performed with the 
approval of the Ethics Committee of the University Hospital, 
and informed written consent was obtained from all of the 
study subjects.
Study design
Study patients received long-term control medication consist-
ing of inhaled glucocorticoids or inhaled glucocorticoids plus 
long-acting inhaled b2 agonists or sustained-release theophyl-
line or a leukotriene modifier or oral glucocorticoids according 
to GINA guidelines,
10 and rapid relief medication consisting of 
two puffs of inhaled salmeterol (100 µg per dose), and two puffs 
of inhaled ipratropium bromide (20 µg per dose) on an as-
needed basis.
Fixed airway obstruction as a functional marker of remodeling 
was defined as forced expiratory volume in one second/forced 
vital capacity (FEV1/FVC) and a predicted FEV1 of less than 
75% following bronchodilator.
12 The emphysema on HRCT, 
near-fatal asthma attacks, asthma duration, atopy, sex, age, and 
body mass index (BMI) were compared in asthmatics and asth-
matics with AR following anti-asthmatic drug for 1 year.
Lung function tests
Baseline FVC and FEV1 measurements were obtained in the 
absence of recent bronchodilator use (within 8 hours) and se-
lected according to the American Thoracic Society criteria.
13 
Basal and post-bronchodilator FEV1, FVC, and forced expirato-
ry flow between 25 and 75% FVC (FEF25-75%) were measured be-
tween 1:00 and 4:00 PM. AHR was measured using the metha-
choline challenge and was expressed as the provocation con-
centration that caused a fall in FEV1 of 20% (PC20), in non-cu-
mulative units.
14
Sputum examination
Sputum
15 was induced using isotonic saline that contained a 
short-acting bronchodilator, as described by Norzila et al.
16 
Samples were treated within 2 hours of collection using the 
method of Pizzichini et al.
17 with a minor modification.
Briefly, all of the visible portions with greater solidity were 
carefully selected and placed in a pre-weighed Eppendorf tube. 
The samples were treated by adding eight volumes of 0.05% di-
thiothreitol (Sputolysin; Calbiochem, San Diego, CA, USA) in 
Dulbecco’s phosphate-buffered saline (D-PBS). One volume of 
protease inhibitor (0.1 M EDTA and 2 mg/mL phenylmethylsul-
fonylfluoride) was added to 100 volumes of homogenized spu-
tum, and the total cell count was determined with a hemocy-
tometer. The homogenized sputum was spun in a cytocentri-
fuge, and 500 cells were read on each sputum slide stained with 
Diff-quick solution (American Scientific Products, Chicago, IL, 
USA).
Allergy skin prick tests
Allergy skin prick tests were performed using using 24 com-
mercial inhalant allergens (Bencard, UK), which included Der-
matophagoides farinae and D. pteronyssinus, cat fur, dog fur, 
cockroaches, and grasses, trees, and ragweed pollens and hista-
mine (1 mg/mL). None of the subjects had received antihista-
mines orally in the 3 days preceding the study. All of the tests 
included positive (1 mg/mL histamine) and negative (diluent) 
controls. After 15 minutes, the mean diameter of the wheals 
formed by the allergens was compared with that formed by his-
tamine. When the former was the same as or larger than the lat-
ter (A/H ratio ≥1.0), the reaction was deemed positive. Atopy 
was determined by the presence of an immediate skin reaction 
to one or more aeroallergens, as described previously.
18
Body mass index
Body mass index (BMI) as an obesity marker was calculated 
as weight/height
2 (kg/m
2).
Aspirin provocation tests
The oral provocation test was performed with increasing dos-
es of aspirin (10-450 mg Astrix; Mayne Pharma Ltd., Melbourne, 
Australia) using a slightly modified method from those de-
scribed previously.
19,20 Provocations always started between 
08:00 and 09:00 AM. Antihistamine and short-acting 2-agonists 
were withdrawn for 24 hours. Changes in FEV1 were followed 
for 5 hours after the last aspirin challenge dose. The maximum Allergy Asthma Immunol Res. 2010 April;2(2):108-113.  doi: 10.4168/aair.2010.2.2.108
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fall in FEV1 during the follow-up period was used as the value 
for the decline of FEV1 by aspirin provocation. Aspirin-induced 
bronchospasm as reflected by rate of FEV1 decline was calcu-
lated as the pre-challenge FEV1 minus the post-challenge FEV1 
divided by the pre-challenge FEV1. Subjects were labeled as 
positive responders if they showed the rate of FEV1 decline of 
more than 15% or skin manifestations. Subjects exhibiting rate 
of FEV1 decline below 15% and absence of nasal or skin symp-
toms were regarded as negative responders (ATA).
Thin-slice CT scanning and radiological evaluation
Thin-slice CT scanning and radiological evaluation. Patients 
underwent volumetric thin section CT scanning of the chest 
using a Somatom 4 scanner (Siemens Medical Systems, Forch-
heim, Germany) as previously described.
21-23
Patients were scanned caudocranially in one breath hold; 1 
mm collimation was used at a table feed of 6 mm/0.75 second 
scanner rotation (8 mm/second) at 120 kV and 140 mA. For the 
expiratory thin section CT scan, all subjects were instructed to 
take a deep breath, exhale all the way, and hold their breath. 
Scanning was performed from the lung bases toward the api-
ces. The volumetric axial images with 1 mm thickness and the 
10 mm intervals were reconstructed with a high spatial fre-
quency algorithm on both end inspiration and end expiration 
scanning. All scans were obtained at suspended end inspirato-
ry volume because artifacts have been reported in scans ob-
tained at functional residual capacity.
24 The images were 
viewed at two window levels of 2,450 HU for accurate measure-
ment of bronchial diameters and 2,700 HU for analysis of other 
HRCT features. All images were displayed at the lung window 
setting using a PACS (picture archiving and communication 
system) workstation (Starpacs, Infinitt Technology). The thin 
section CT scans were evaluated for the presence and/or extent 
of the emphysema. These findings were defined according to 
the glossary of terms recommended by the Fleischner Society.
24
Statistical analysis
Variables differences were compared at the period of asthma 
and AR diagnosis and the physiologic fixed airway obstruction 
Table 1.  Clinical profiles of the subjects
Bronchial asthma Bronchial asthma
with allergic rhinitis
No. of subjects (male/female) 485 (183/302) 428 (161/267)
Age (yr) 36.7±0.40 34.8±0.45
Sex (male/female) 183/302 161/267
Duration of asthma (yr) 6.01±0.33 5.56±0.30
FEV1, % predicted  86.4±0.97 86.7±1.00
FVC, % predicted  86.3±0.97 85.8±0.88
FEV1/FVC 79.4±0.59 81.3±0.53
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
following anti-asthmatic drug for 1 year were compared. Group 
differences were compared using two-sample t-tests, Wilcoxon 
rank-sum tests, and the Pearson c
2 test for normally distributed, 
skewed, and categorical data, respectively. A P value less than 
0.05 was considered statistically significant.
RESULTS
The 46.8% (428/913) asthmatics suffered from AR (Table 1). 
There were no differences of total IgE (263.1±25.5 IU versus 
318.3±20.4 IU), body mass index (23.1±0.2 kg/m
2 versus 23.1± 
0.3), PC20 (6.06±0.44 mg/mL versus 6.31±0.47 mg/mL), spu-
tum eosinophils (3.20±0.67% versus 3.43±0.62%), sputum neu-
trophils (26.0±2.11% versus 24.9±2.06%), and emphysema on 
HRCT (1/36 versus 2/40) in between asthmatics and those with 
AR. Asthma duration was not different between asthmatics and 
those with rhinitis. The age in asthmatics was higher than that 
in asthmatics with AR (36.7±0.4 versus 34.8±0.45, P=0.001, Fig. 
1). Although there were no differences of post bronchodilator 
FEV1 % predicted (86.4±1.15% versus 86.7±1.00%) and post 
bronchodilator FVC % predicted (86.3±0.97% versus 85.8± 
0.88%) and post bronchodilator FEF (75.8±1.67% versus 79.5± 
1.60%) in two groups, post bronchodilator FEV1/FVC (79.4± 
0.59% versus 81.3±0.53%, P=0.018, Fig. 2) was lower in asthmat-
ics than in those with AR. The prevalence of atopy [296/428 
(69.1%) versus 232/485 (47.8%), P=0.001] was higher in asth-
matics with AR than in asthmatics. The prevalence of aspirin in-
tolerance in tested patients was 10.09% (55/545). Aspirin intol-
erance was higher in asthmatics with AR than in asthmatics 
[42/218 (19.2%) versus 13/109 (11.9%), P=0.001, Fig. 3]. Fixed 
airway obstruction defined as a functional marker of remodel-
ing was defined as FEV1/FVC and a predicted FEV1 of less than 
75% following bronchodilator were more observed in asthmat-
ics than in those with AR [39/319 (12.2%) versus 28/355 (7.8%), 
P=0.001, Fig. 4] after treatment with inhaled steroid and other 
anti-asthma medications for no less than 1 year.
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DISCUSSION
Asthmatics with AR had more atopy prevalence and aspirin 
intolerance than those in asthmatics, and asthmatics had poor 
response to anti-inflammatory drugs than in asthmatics with 
AR, indicating that asthmatics have more fixed airway obstruc-
tion than combined AR in asthmatics and concurrent rhinitis in 
asthmatics may be a favorable factor in terms of treatment.
There is a link between AR and asthma. Asthma and AR can 
be associated both with an IgE-mediated allergic reaction and 
an inflammatory pattern. 28-50% of asthmatic patients had AR 
compared to 10-20% in the general population.
6 AR is associat-
ed to asthma and constitutes an independent risk factor for its 
occurrence.
1 Our data showing 46.8% prevalence of AR in the 
asthmatics is in good agreement with the previous reports. And 
asthmatics with AR had more atopy prevalence than asthmat-
ics, indicating that combined AR in asthmatics be positive skin 
test results to common aeroallergens.
Many patients with AR who have no perceived asthma symp-
toms have BHR to natural stimuli such as exercise or to bron-
chial challenge with chemical stimuli such as histamine and 
methacholine, especially during AR exacerbation.
6 Simons
25 
suggested that the new term “allergic rhinobronchitis” accu-
rately describe chronic allergic inflammation throughout the 
airways of patients with concurrent AR and asthma and recom-
mended the key to management of both disorders lies in ad-
dressing the common immunopathologic mechanisms and in 
preventing and relieving chronic allergic inflammation, not 
only with appropriate pharmacologic treatment but also by rec-
ommending allergen avoidance and in selected patients, spe-
cific immunotherapy. When it comes to looking at patients with 
asthma we should considerate combined asthma and rhinitis 
to treat both asthma and AR.
The underlying pathologic processes are similar in the upper 
and lower airways.
3 Immune effector cells responsible for aller-
gic reactions in both the lung and nose include, most promi-
nently, mast cell, T lymphocytes, and eosinophils.
26-28 Eosino-
phils are characteristic for acute and chronic inflammatory 
changes observed in asthma and AR and have also been impli-
cated in many aspects of tissue damage that occurs at sites of 
chronic inflammation. In this study there are no differences of 
sputum eosinophils between asthmatics and asthmatics with 
AR. Sputum eosinophils did not make a differentiation be-
tween asthmatics and asthmatics with AR. Further studies will 
be needed to define the role of inflammatory cells between up-
per and lower airways.
AR patients who had hyperresponsive to methacholine were 
at significantly greater risk of developing asthma than those 
with normal bronchial challenge.
29 Upper airway inflammatory 
processes occurring totally or primarily in the upper airway 
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Fig. 4.  Fixed airway obstruction between asthmatics and those with AR fol-
lowing anti-inflammatory drug for 1 year.
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Fig. 3.  Aspirin intolerance between asthmatics and those with AR. Aspirin in-
tolerance defined as showing symptoms with a fall in FEV1 greater than 15% 
following aspirin provocation test in patients.
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Fig. 2.  Lung function following bronchodilator between asthmatics and those 
with allergic rhinitis. A: asthmatics, B: asthmatics with allergic rhinitis. FEV1, 
forced expiratory volume in 1 second; FVC, forced vital capacity.
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may participate in the pathogenesis of BHR and asthma.
29 
Rhinitis subjects with BHR develop asthma more frequently 
than those without.
6,29 In this study there are no differences of 
PC20 between BA and BA with AR. Further studies would be 
needed to determine the time point change of AR to BA.
Airway remodeling plays an important role in the pathophysi-
ology of asthma phenotypes, such as BHR and airway inflam-
mation, in patients with asthma.
30-34 Airway remodeling is linked 
to AHR via diverse triggers and a steeper trajectory of the long-
term decrease in lung function in asthmatic patients.
35
Common mucosal inflammatory responses occur in com-
bined AR and asthma syndrome. The current best practice is to 
treat asthma conventionally with inhaled corticosteroid with or 
without b2 agonist and to add intranasal corticosteroid to im-
prove specific rhinitis symptoms.
36,37 In this study fixed airway 
obstruction defined as a functional marker of remodeling was 
defined as FEV1/FVC and a predicted FEV1 of less than 75% fol-
lowing bronchodilator
12 were more observed in asthmatics than 
in asthmatics with AR after anti-inflammatory drug for 1 year.
The authors
12,37,38 reported that non atopy, asthma duration, 
emphysema on high-resolution computed tomography, spu-
tum eosinophils, age, and BMI before antiasthma treatment are 
important factors related to airway remodeling in patients with 
asthma and the FEV1 percent predicted and the blood and spu-
tum eosinophil levels prior to GC inhalation are associated with 
the responsiveness to inhaled GCs in patients with moderate-
to severe asthma.
Our study suggest that non-atopy and emphysema on HRCT, 
and age may be important discriminators of asthmatics with 
AR and asthmatics and asthmatics with concurrent AR may 
have suffered from diseases for longer duration in agreement to 
previous studies.
12,37,38 Those results imply that just asthmatics 
have more airway remodeling and early diagnosis and early 
treatment is necessary for preventing airway remodeling.
Aspirin and non-steroidal anti-inflammatory drugs (NSAID) 
specifically inhibit cyclo-oxygenase (prostaglandin-endoperox-
ide synthase), leading to a reduction in prostaglandin E2 and 
overproduction of cysteinyl leukotrienes.
39 Aspirin-intolerant 
asthma (AIA), the development of bronchoconstriction in asth-
matic individuals following the ingestion of aspirin or other 
NSAID, affects 5-10% of asthmatic adults.
40,41 In this study, we 
compared aspirin provocation tests between BA and BA with 
AR. Patients with BA with AR had more aspirin tolerance, sug-
gesting that combined AR in asthmatics have more aspirin in-
tolerance and especially those patients should treated cautious-
ly by aspirin. Our results in the contrary of previous reports
40,41 
that AIA is more prevalent in non-allergic rhinosinusitis may be 
possible due to only including patients done with aspirin prov-
ocation test.
In conclusion asthmatics with AR had more atopy and aspirin 
intolerance than those in asthmatics, and asthmatics had poor 
response to anti-inflammatory drugs than in asthmatics with 
AR, indicating that combined AR in asthmatics may be a favor-
able factor in terms of treatment and we should treat concur-
rently both asthma and AR.
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